---
title: Ondansetron
category: drug
feed: show
date: 15-05-2023
tags: Drug 
author: Dragoman
---

## Mechanism of Action [^1][^2]
- Ondansetron is a selective **5-HT₃ receptor antagonist** that blocks serotonin receptors in the **chemoreceptor trigger zone (CTZ)**, preventing the initiation of the vomiting reflex.

## Indications [^1][^2]
- Prophylaxis and treatment of **postoperative nausea and vomiting (PONV)**.

## Dosage [^1][^3]
- **Postoperative Nausea and Vomiting (PONV) Prophylaxis:**
  - **Adults:** 4 mg IV over 2-5 minutes at the end of surgery.
  - **Children:** 0.1 mg/kg IV (up to 4 mg) at the end of surgery.
- **Oral:** 8 mg orally, 1 hour before anesthesia or chemotherapy (50% bioavailability).

## Complications [^1][^2]
- **Headache:** Common, with a number needed to harm (NNH) of 36.
- **QTc Prolongation:** May prolong the QT interval
- **Constipation:** NNH of 23.
- **Elevated Liver Enzymes:** NNH of 31, though often transient and clinically insignificant.

## Pharmacokinetics [^2]
- **Onset of Action:** 30 to 60 minutes after oral or IV administration.
- **Metabolism:** Hepatic
- **Elimination Half-life:** 3 to 4 hours.
- **Excretion:** Primarily through urine as metabolites.

## References
[^1]: Gan, T.J., Belani, K.G., Bergese, S., et al. (2020). Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg.
[^2]: Shafer SL, Rathmell JP, Flood P. *Stoelting’s Pharmacology and Physiology in Anesthetic Practice.* Fifth edition. Philadelphia: Wolters Kluwer Health, 2015.
[^3]: Coté CJ, Lerman J, Anderson BJ. *A Practice of Anesthesia for Infants and Children.* Seventh edition. Philadelphia, PA: Elsevier, 2024.
